Staton Carolyn A, Lewis Claire E
Microcirculation Research Group, University of Sheffield Medical School, Sheffield, S10 2RX, UK.
J Cell Mol Med. 2005 Apr-Jun;9(2):286-302. doi: 10.1111/j.1582-4934.2005.tb00356.x.
Angiogenesis, the development of new blood vessels from the existing vasculature, and haemostasis, the coagulation cascade leading to formation of a clot, are among the most consistent host responses associated with cancer. Importantly, these two pathways interrelate, with blood coagulation and fibrinolysis influencing tumor angiogenesis directly, thereby contributing to tumor growth. Moreover, many endogenous inhibitors of angiogenesis are found within platelets or harboured as cryptic fragments of haemostatic proteins. In this review we outline ways in which angiogenesis is coordinated and regulated by haemostasis in human cancer. Then we detail the experimental and pre-clinical evidence for the ability of many of these endogenous proteins to inhibit tumor angiogenesis and thus their potential to be anti-cancer agents, with particular reference to any clinical trials.
血管生成,即从现有脉管系统发育出新的血管,以及止血,即导致血凝块形成的凝血级联反应,是与癌症相关的最常见宿主反应。重要的是,这两条途径相互关联,血液凝固和纤维蛋白溶解直接影响肿瘤血管生成,从而促进肿瘤生长。此外,许多血管生成的内源性抑制剂存在于血小板中,或作为止血蛋白的隐蔽片段存在。在本综述中,我们概述了人类癌症中止血对血管生成的协调和调节方式。然后,我们详细阐述了许多这些内源性蛋白抑制肿瘤血管生成的能力的实验和临床前证据,以及它们作为抗癌药物的潜力,特别提及了任何临床试验。